what are the fda approved glp 1 drugs How Employers Can Optimize Benefits in Era of GLP-1s The U.S. Food and Drug

The present recommendations of the American and European Diabetes Associations are currently updating their actual recommendation for the treatment algorithm for T2D (17)

Patients with personal MTC history or Multiple Endocrine Neoplasia type 2 (MEN2) syndromewhich includes familial MTCshould not use semaglutide, tirzepatide, or any GLP-1 compound

Albiglutide once weekly also showed a cardiovascular benefit but is no longer marketed, as mentioned previously (27)

However, a drawback of these medicines has been the necessity for administration by subcutaneous injection, which limits patient utilization and may reduce opportunities for fixed-dose combination treatments with other small-molecule drugs

Factors fueling this expansion include rising demand for weight management therapies, advancements in peptide drug innovation, and the focus on chronic disease management and personalized medicine